Figure 2

Serum sTRAIL levels after treatment. Elevated levels of sTRAIL were found in seven out of 16 metastatic colon cancer patients whose serum sTRAIL concentrations were similar to those of healthy age- and sex-matched control individuals (n = 10) before bevacizumab therapy, as seen in Figure 1. These increases were significant compared with pretreatment measurements (P < 0.001). The increase or decrease in the serum levels were shown as percentage change in serum sTRAIL.